Business
INVO Bioscience to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ -- INVO
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET\n\n\nSARASOTA, Fla., Aug. 5, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, will report financial results for its second quarter 2021, ended June 30, 2021, after the market close on Monday, August 16, 2021. The Company has scheduled a conference call that same day, Monday, August 16, 2021, at 4:30 pm ET, to review the results. \n\n \n \n \n \n \n \n\n \nSecond Quarter 2021 Conference Call Details\nDate and Time: Monday, August 16, 2021 at 4:30 pm ET\nCall-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751. \nLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://www.webcaster4.com/Webcast/Page/2162/42110. \nReplay: A teleconference replay of the call will be available through August 23, 2021 at 877-344-7529 or 412-317-0088, confirmation # 10158496. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. \nAbout INVO Bioscience\nWe are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, p...